Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C P Cannon

Showing results (111-120 of 149) with videos related to

Pageof 15
Sort By:
Circulation|April 20, 1999
Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study GroupC M Gibson, S A Murphy, M J Rizzo, et al.
American Heart Journal|January 3, 2001
Determination of a weight-adjusted dose of TNK-tissue plasminogen activatorF Wang-Clow, N L Fox, C P Cannon, et al.
Journal of the American College of Cardiology|March 1, 1995
Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trialC M Gibson, C P Cannon, R N Piana, et al.
American Heart Journal|April 30, 2017
Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics, L Bowman, F Chen, et al.
The New England Journal of Medicine|October 31, 1996
Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromesE M Antman, M J Tanasijevic, B Thompson, et al.
American Heart Journal|April 30, 1999
Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 InvestigatorsF Van de Werf, C P Cannon, A Luyten, et al.
Journal of the American College of Cardiology|December 1, 1994
Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trialC P Cannon, C H McCabe, D J Diver, et al.
Annals of Emergency Medicine|April 28, 2000
National Heart Attack Alert Program position paper: chest pain centers and programs for the evaluation of acute cardiac ischemiaR J Zalenski, H P Selker, C P Cannon, et al.
JAMA|June 24, 2000
Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarctionC P Cannon, C M Gibson, C T Lambrew, et al.
Circulation|March 1, 1996
TIMI frame count: a quantitative method of assessing coronary artery flowC M Gibson, C P Cannon, W L Daley, et al.
Pageof 15

Showing results (111-120 of 149) with videos related to

Sort By:
Pageof 15
Circulation|April 20, 1999
Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study GroupC M Gibson, S A Murphy, M J Rizzo, et al.
American Heart Journal|January 3, 2001
Determination of a weight-adjusted dose of TNK-tissue plasminogen activatorF Wang-Clow, N L Fox, C P Cannon, et al.
Journal of the American College of Cardiology|March 1, 1995
Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trialC M Gibson, C P Cannon, R N Piana, et al.
American Heart Journal|April 30, 2017
Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics, L Bowman, F Chen, et al.
The New England Journal of Medicine|October 31, 1996
Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromesE M Antman, M J Tanasijevic, B Thompson, et al.
American Heart Journal|April 30, 1999
Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 InvestigatorsF Van de Werf, C P Cannon, A Luyten, et al.
Journal of the American College of Cardiology|December 1, 1994
Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trialC P Cannon, C H McCabe, D J Diver, et al.
Annals of Emergency Medicine|April 28, 2000
National Heart Attack Alert Program position paper: chest pain centers and programs for the evaluation of acute cardiac ischemiaR J Zalenski, H P Selker, C P Cannon, et al.
JAMA|June 24, 2000
Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarctionC P Cannon, C M Gibson, C T Lambrew, et al.
Circulation|March 1, 1996
TIMI frame count: a quantitative method of assessing coronary artery flowC M Gibson, C P Cannon, W L Daley, et al.
Pageof 15